Generalized pustular psoriasis registry in Costa Rica
Part of Skin clinical trials.
This study is creating a registry of people with generalized pustular psoriasis (a rare, severe skin condition with pus-filled blisters). The goal is to learn more about this condition and how it affects patients in Costa Rica. If you have a confirmed diagnosis, this registry may help researchers better understand GPP and improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of generalized pustular psoriasis (GPP) made by a skin doctor.
- Your diagnosis must be recorded in the Costa Rican health system's electronic records.
- You can be any age and either male or female.
- You must be receiving care at a hospital or clinic in the Costa Rican Social Security system.
- Your medical records must have enough information to be used in the registry.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry tracks the safety and effectiveness of GPP treatments in real-world settings. It helps doctors and researchers learn how well current and future medicines work for people with generalized pustular psoriasis.
This study tests an experimental drug called HB0034 for people with a sudden, severe flare of generalized pustular psoriasis (GPP). It aims to see if the drug can safely clear the pustules and improve symptoms.
This trial is for people who have already taken part in an earlier study of the drug HB0034 for generalized pustular psoriasis (GPP). It checks how safe and effective the drug is over a longer period of time.
This study looks at medical records of children and teens in Costa Rica who have psoriasis. It aims to understand how common it is, what treatments are used, and how it affects their health.
This registry collects information from patients with psoriatic disease (psoriasis or psoriatic arthritis) who are being treated with IL-23 inhibitors (guselkumab or risankizumab) in Costa Rican public health centers. The goal is to better understand real-world outcomes and safety.
This study looks at how well two types of advanced medications, dupilumab and JAK inhibitors, work for people with moderate-to-severe atopic dermatitis. It helps doctors learn which treatments are most effective in real-world settings.
Hear when a new Generalized Pustular Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.